08.11.25 -- AI Meets CDMO: Smarter Outsourcing For Biologics And Cell And Gene Therapies

Ready to scale smarter? Join Boehringer Ingelheim’s webinar to discover how modular N‑1 perfusion transforms upstream biologics manufacturing—boosting inoculum density, speeding up seed trains, and easing facility strain. Learn how to bridge the scale-up gap and future-proof your process for commercial success. Don’t miss out—register now to reserve your spot! Click here to learn more.

By leveraging technologies together with transposon design to achieve semi-targeted integration, drug developers can achieve more efficient and consistent production.

Explore how CMOs are playing a pivotal role in enabling pharmaceutical companies to optimize their operations and how this collaboration is reshaping the future of pharmaceutical manufacturing.

Gain a thorough understanding of the Fc region of your antibody product and how to use a risk-based approach to strategically test its functionality, efficacy, and development.

Chief Editor Louis Garguilo analyzes a report projecting the biologics CDMO secondary packaging market could rise from $2.59 billion this year to USD $5.50 billion by 2034. Projecting so far into the future is tricky business, but Garguilo explains the ultimate value.

An increasing number of poorly soluble APIs are the cornerstone of cutting-edge therapies, necessitating equally complex formulation technologies to maintain or improve solubility and, ultimately, bioavailability.

Examine the unique considerations for rare diseases that create hurdles, making it difficult to design and implement a drug development program.

Review a semi-automated method for dynamically assessing plunger migration under controlled variations in temperature and pressure, utilizing computer vision tools.

Advances in release drug delivery could improve efficiency and consistency in drug release, manifesting real-life advantages for patients in the form of enhanced accessibility and compliance.

Observe an established and qualified GMP microbiology lab in Ireland, providing expertise, staffing, training, and project management to ensure compliant operations and client success.

Whether you’re at the discovery stage or thinking about commercial production, gain useful insights on expression formats from transient transfection, through stable pools to stable clones.

Size homogeneity of a mAb in solution is crucial for comparability and characterization. Here, an IgG1 antibody was cleaved into antigen-binding fragments via pepsin and papain digestion, then purified.

Uncover how to transform biopharma learning with a human-centered, AI-enhanced ecosystem that personalizes development, fosters engagement, and aligns training with real-world impact.

Learn how leveraging the expertise and flexibility of a partner empowers you to ensure regulatory compliance from the outset, with thorough characterization starting at the earliest stages.

Our multi-product facilities feature state-of-the-art equipment for animal cell-derived viral and microbial products for your clinical trials in phase 1-2.

Discover how our end-to-end Drug Product capabilities support the full lifecycle of biologics, seamlessly integrated with our extensive drug substance network across diverse modalities.

As pressure to accelerate timelines mounts, finding a CDMO committed to optimizing processes with innovative technologies is key for adding efficiency while maintaining high quality standards.

Our 87,000 sq. ft. cGMP-certified drug product manufacturing facility, located in Baltimore, Maryland, offers aseptic fill/finish manufacturing of biologics and sterile injectables.